10-QPeriod: Q1 FY2025

Cencora, Inc. Quarterly Report for Q1 Ended Dec 31, 2024

Filed February 5, 2025For Securities:COR

Summary

Cencora, Inc. reported strong revenue growth in the fourth quarter of fiscal year 2024, with a 12.8% increase year-over-year, driven primarily by its U.S. Healthcare Solutions segment. This growth was bolstered by significant sales of GLP-1 class products for diabetes and weight loss, as well as increased specialty product sales. Despite the revenue surge, net income attributable to Cencora, Inc. saw a decline to $488.6 million from $601.5 million in the prior year's comparable period, leading to a decrease in diluted earnings per share from $2.98 to $2.50. This profitability dip can be attributed to higher operating expenses, including increased litigation and opioid-related expenses, and a decrease in gains from antitrust litigation settlements. The company also completed a significant acquisition of Retina Consultants of America (RCA) for $4.4 billion in early January 2025, further impacting its financial position and future growth trajectory.

Financial Highlights

56 data points
Beta

Revenue

$81.49B

3.1% Gross Margin

Net Income

$488.60M

0.6% Net Margin

EPS (Diluted)

$2.50

Total Assets

$69.05B

Cash & Equivalents

$3.22B

Free Cash Flow

-$2.82B

Financial Statements
Beta
Revenue$81.49B
Cost of Revenue$78.93B
Gross Profit$2.56B
SG&A Expenses$1.47B
Operating Expenses$1.59B
Operating Income$706.25M
Net Income$488.60M
EPS (Basic)$2.52
EPS (Diluted)$2.50
Shares Outstanding (Basic)193.76M
Shares Outstanding (Diluted)195.19M

Key Highlights

  • 1Revenue increased by 12.8% year-over-year to $81.5 billion, driven by a 13.6% increase in the U.S. Healthcare Solutions segment.
  • 2Sales of GLP-1 class products for diabetes and weight loss contributed $3.2 billion in increased revenue.
  • 3Net income attributable to Cencora, Inc. decreased to $488.6 million from $601.5 million in the prior year's quarter.
  • 4Diluted earnings per share declined to $2.50 from $2.98 year-over-year.
  • 5Operating expenses increased by 12.5%, notably due to higher litigation and opioid-related expenses compared to a credit in the prior year.
  • 6Cencora completed the acquisition of Retina Consultants of America (RCA) for $4.4 billion in early January 2025.
  • 7The company repurchased $385.4 million of its common stock during the quarter and increased its quarterly dividend by 8%.

Frequently Asked Questions

The primary driver of Cencora's revenue growth was the U.S. Healthcare Solutions segment, which saw a 13.6% increase. This growth was significantly boosted by a 53.0% increase in sales of GLP-1 class products for diabetes and weight loss, totaling $3.2 billion, and increased sales of specialty products to physician practices and health systems.

Despite a significant increase in revenue, Cencora's net income attributable to the company decreased from $601.5 million to $488.6 million. This was primarily due to a substantial rise in operating expenses, which grew by 12.5%. Key contributors to this increase included higher litigation and opioid-related expenses, which were a credit in the prior year, and a decrease in gains from antitrust litigation settlements.

Cencora acquired an 85% interest in Retina Consultants of America (RCA) for $4.4 billion in early January 2025. RCA's results will be consolidated into the U.S. Healthcare Solutions segment. This significant acquisition is expected to contribute to future growth but also involved substantial cash outlay and potential contingent consideration, impacting the company's financial position and capital structure.

Cencora has actively managed its debt and liquidity. During the quarter, the company issued $1.8 billion in senior notes and drew on revolving credit facilities, partly to finance the RCA acquisition. It also has significant availability under its multi-currency revolving credit facility and receivables securitization facility. The company also repurchased shares and increased its dividend, demonstrating confidence in its financial position, while noting expected increases in interest expense due to new debt.